Imperial College Health Partners (ICHP) are excited to announce a partnership with Medopad, a leading UK healthcare AI company.
Medopad lead on mobile health solutions which connect patients and healthcare professionals in real-time, including patient self-care apps and remote patient monitoring.
The collaboration will enable ICHP’s partner organisations to work with Medopad on existing innovations, helping to improve diagnosis, enhance patient treatment and empower both clinicians and patients.
Medopad have also entered into a number of other strategic partnerships with leading healthcare, technology and academic institutions including; Royal Free NHS Hospital, Guy’s and St Thomas’ NHS Hospital, Barts Health, China Resources, HP, Lenovo, Johns Hopkins University, and Peking University. These formed part of £100M of deals announced during the Prime Minister’s trade mission to China. In addition Medopad and Tencent signed a partnership to work together on developing next generation medical AI.
Dr. Axel Heitmueller, Managing Director at ICHP, said: “This is an exciting time for technology, data and the provision for healthcare. Partnering with leading, forward thinking organisations like Medopad is invaluable to our members as we continue to drive innovation across the NHS. We look forward to working together for the benefit this will bring for patients.”
Dan Vahdat, CEO of Medopad, commented: “Medopad is at a very exciting moment in its history as we begin to massively scale our operation. Part of our strategy is to partner with leading organisations, like ICHP, to help us deliver market leading new technologies based on latest medical and clinical research that are scientifically validated. Our aim is to work with academia, hospitals, pharma and the biggest technology companies in the world to improve the lives of patients globally”
